European SPC Manufacturing Waiver Comes Into Effect
Timeline: Key Events For The Development Of A Waiver To Allow Manufacturing And Stockpiling For Day-One Launch
In Vivo has traced the history of the newly affirmed European SPC manufacturing waiver from early industry lobbying efforts to its ultimate entry into force. The mechanism has been met with controversy throughout its evolution.
You may also be interested in...
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.
Sandoz and Aurobindo have mutually agreed to terminate their billion-dollar agreement that would have seen the Indian company acquire Sandoz’ dermatology and oral solids businesses in the US, citing a delay in FTC approval for the deal.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.